Attached files
file | filename |
---|---|
EX-10.14 - EX-10.14 - Finch Therapeutics Group, Inc. | d54314dex1014.htm |
EX-10.13 - EX-10.13 - Finch Therapeutics Group, Inc. | d54314dex1013.htm |
EX-10.12 - EX-10.12 - Finch Therapeutics Group, Inc. | d54314dex1012.htm |
EX-10.11 - EX-10.11 - Finch Therapeutics Group, Inc. | d54314dex1011.htm |
EX-10.10 - EX-10.10 - Finch Therapeutics Group, Inc. | d54314dex1010.htm |
EX-10.2 - EX-10.2 - Finch Therapeutics Group, Inc. | d54314dex102.htm |
EX-5.1 - EX-5.1 - Finch Therapeutics Group, Inc. | d54314dex51.htm |
EX-4.2 - EX-4.2 - Finch Therapeutics Group, Inc. | d54314dex42.htm |
EX-3.4 - EX-3.4 - Finch Therapeutics Group, Inc. | d54314dex34.htm |
EX-3.3 - EX-3.3 - Finch Therapeutics Group, Inc. | d54314dex33.htm |
EX-3.1 - EX-3.1 - Finch Therapeutics Group, Inc. | d54314dex31.htm |
EX-1.1 - EX-1.1 - Finch Therapeutics Group, Inc. | d54314dex11.htm |
S-1/A - S-1/A - Finch Therapeutics Group, Inc. | d54314ds1a.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Amendment No. 1 to Registration Statement on Form S-1 (No. 333-253622) of our report dated February 26, 2021 (March 15, 2021, as to the subsequent events described in Note 16), relating to the consolidated financial statements of Finch Therapeutics Group, Inc. and its subsidiaries. We also consent to the reference to us under the heading Experts in such Registration Statement.
/s/ Deloitte & Touche LLP |
Boston, Massachusetts |
March 15, 2021 |